Glaukos Corp (Glaukos) is an ophthalmic medical device company that researches and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as micro stent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- to moderate-open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.
Headquarters
United States of America
Address
1 Glaukos Way, Aliso Viejo, California, 92656
Website
www.glaukos.com
Telephone
1 949 3679600
No of Employees
907
Industry
Medical Equipment
Ticker Symbol & Exchange
GKOS (NYSE)
Revenue (2022)
$314.7M
11.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-35.8%
(2022 vs 2021)
Market Cap*
$4.8B
Net Profit Margin (2022)
XYZ
-22.0%
(2022 vs 2021)
* As of and is in US$
Glaukos Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ophthalmic Medical Device | Glaukos |
| iStent Trabecular Micro-Bypass Stent | iStent |
Competitor Comparison
| Key Parameters | Glaukos Corp | STAAR Surgical Company | LivaNova USA Inc | IRIDEX Corporation (US) |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Aliso Viejo | Lake Forest | Houston | - |
| State/Province | California | California | Texas | California |
| No. of Employees | 907 | 1,056 | - | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas W. Burns | Chairman; Chief Executive Officer; President | Executive Board | 2022 | 62 |
| Alex R. Thurman | Chief Financial Officer; Senior Vice President | Senior Management | 2022 | 53 |
| Joseph E. Gilliam | President; Chief Operating Officer | Senior Management | 2022 | 47 |
| Jay L. Katz, MD | Chief Medical Officer | Senior Management | 2017 | - |
| Chris M. Calcaterra | Executive Vice President - Global Commercial Operations | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward